VRCA Verrica Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VRCA

Price (delayed)

$7.26

Market cap

$307.96M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.48

Enterprise value

$283.92M

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica's late-stage product candidate, VP-102, is in development to treat molluscum contagiosum (molluscum), common warts and ...

Highlights
Verrica Pharmaceuticals's gross profit has soared by 64% from the previous quarter but it has decreased by 47% YoY
The revenue has surged by 60% since the previous quarter but it has declined by 43% year-on-year
The net income has plunged by 174% YoY and by 39% from the previous quarter
The EPS has dropped by 106% year-on-year and by 38% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.verrica.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of VRCA
Market
Shares outstanding
42.42M
Market cap
$307.96M
Enterprise value
$283.92M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
15.45
Price to sales (P/S)
64.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
55.41
Earnings
Revenue
$5.12M
EBIT
-$63.03M
EBITDA
-$62.2M
Free cash flow
-$38.94M
Per share
EPS
-$1.48
Free cash flow per share
-$0.86
Book value per share
$0.47
Revenue per share
$0.11
TBVPS
$1.8
Balance sheet
Total assets
$81.6M
Total liabilities
$61.83M
Debt
$45.51M
Equity
$19.76M
Working capital
$60.51M
Liquidity
Debt to equity
2.3
Current ratio
4.55
Quick ratio
4.34
Net debt/EBITDA
0.39
Margins
EBITDA margin
-1,213.8%
Gross margin
85.4%
Net margin
-1,307.5%
Operating margin
-1,283.4%
Efficiency
Return on assets
-86.6%
Return on equity
-147%
Return on invested capital
-262.6%
Return on capital employed
-97.6%
Return on sales
-1,230.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VRCA stock price

How has the Verrica Pharmaceuticals stock price performed over time
Intraday
7.4%
1 week
5.68%
1 month
17.86%
1 year
11.18%
YTD
-0.82%
QTD
22.64%

Financial performance

How have Verrica Pharmaceuticals's revenue and profit performed over time
Revenue
$5.12M
Gross profit
$4.38M
Operating income
-$65.76M
Net income
-$67M
Gross margin
85.4%
Net margin
-1,307.5%
The net income has plunged by 174% YoY and by 39% from the previous quarter
Verrica Pharmaceuticals's gross profit has soared by 64% from the previous quarter but it has decreased by 47% YoY
The revenue has surged by 60% since the previous quarter but it has declined by 43% year-on-year
VRCA's operating income is down by 35% since the previous quarter

Growth

What is Verrica Pharmaceuticals's growth rate over time

Valuation

What is Verrica Pharmaceuticals stock price valuation
P/E
N/A
P/B
15.45
P/S
64.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
55.41
The EPS has dropped by 106% year-on-year and by 38% since the previous quarter
VRCA's price to book (P/B) is 158% more than its 5-year quarterly average of 6.0 and 121% more than its last 4 quarters average of 7.0
The equity has dropped by 53% since the previous quarter and by 51% year-on-year
The revenue has surged by 60% since the previous quarter but it has declined by 43% year-on-year
The stock's price to sales (P/S) is 40% more than its last 4 quarters average of 46.0

Efficiency

How efficient is Verrica Pharmaceuticals business performance
The return on assets has dropped by 102% year-on-year and by 22% since the previous quarter
The ROE has plunged by 90% YoY and by 54% from the previous quarter
The return on invested capital has dropped by 77% year-on-year but it has increased by 10% since the previous quarter
The ROS is up by 16% since the previous quarter

Dividends

What is VRCA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRCA.

Financial health

How did Verrica Pharmaceuticals financials performed over time
Verrica Pharmaceuticals's total assets is 32% higher than its total liabilities
Verrica Pharmaceuticals's total assets has surged by 82% YoY but it has decreased by 16% QoQ
Verrica Pharmaceuticals's current ratio has shrunk by 60% YoY and by 44% QoQ
VRCA's debt is 130% higher than its equity
Verrica Pharmaceuticals's debt to equity has soared by 121% from the previous quarter
The equity has dropped by 53% since the previous quarter and by 51% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.